AMRI scooped up in $920M deal as contract manufacturing M&A rolls on

pills
Significant consolidation in the contract manufacturing market continues unabated with the latest deal for AMRI.

Albany, New York-based AMRI has agreed to a buyout worth more than $920 million as the M&A market for contract manufacturers continues to run hot. The deal comes just weeks after one of the big boys among CDMO players, Patheon, agreed to an acquisition valued at $7.2 billion.

AMRI, short for Albany Molecular Research, Inc., agreed to sell to private equity investors The Carlyle Group and GTCR for $21.75 per share in cash, which it says is a 42% premium over the price of AMRI stock the day before rumors of a potential sale surfaced.

AMRI, which has grown its business through a series of buyouts of its own, last month reported Q1 2017 revenues of $163.8 million, up 55% from 2016, and adjusted EBITDA up 83% to $24 million, but a loss of $10.7 million.

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: AMRI adds EU API supplier to its stable with $358M deal

Last year, AMRI picked up Lodi, Italy-based Euticals in a $358 million deal. It got API facilities primarily in Italy, Germany, France and in Springfield, Missouri, with the deal. In 2014, it did a couple of deals for smaller companies.

There has been significant consolidation in the contract manufacturing market, as a handful of companies have bought competitors to get their hands on specialized services or geographic reach. That in turn has attracted even bigger companies that see growth in the field as a good bet, as pharma players often turn to contractors rather than build new plants.

In May, Waltham, Massachusetts-based Thermo Fisher agreed to pay $35 a share for Patheon, a sum that amounts to about $5.2 billion, and assume another $2 billion in debt for the Durham, North Carolina-based CDMO. Patheon has also done a series of deals to build its business.

RELATED: Patheon, built on a series of acquisitions, is snapped up by Thermo Fisher in $7.2B deal

Switzerland-based CDMO leader Lonza last year snapped up U.S.-based contract capsule and drug producer Capsugel in a $5.5 billion deal and contract player Catalent bought softgel capsule maker Accucaps last year for an undisclosed amount.   

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

As flights from China contract and prices double, the logistics of getting products out of China is a major challenge. 

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.